MCID: FLL003
MIFTS: 38

Fallopian Tube Endometrioid Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Endometrioid Adenocarcinoma:

Name: Fallopian Tube Endometrioid Adenocarcinoma 12 15 74
Endometrioid Carcinoma of the Fallopian Tube 12
Fallopian Tube Endometrioid Neoplasm 12
Fallopian Tube Endometrioid Cancer 12
Fallopian Tube Endometrioid Tumor 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5831
NCIt 51 C40111 C6279

Summaries for Fallopian Tube Endometrioid Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from endometrial epithelial cells of glandular origin.

MalaCards based summary : Fallopian Tube Endometrioid Adenocarcinoma, also known as endometrioid carcinoma of the fallopian tube, is related to adenomyoma and cervical adenocarcinoma. An important gene associated with Fallopian Tube Endometrioid Adenocarcinoma is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are Bladder cancer and Platinum drug resistance. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lung, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and homeostasis/metabolism

Related Diseases for Fallopian Tube Endometrioid Adenocarcinoma

Diseases related to Fallopian Tube Endometrioid Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 adenomyoma 10.2
2 cervical adenocarcinoma 10.2 CDKN2A ERBB2
3 breast papillomatosis 10.2 CDKN2A ERBB2
4 meningeal melanocytoma 10.2 CDKN2A MME
5 vulval paget's disease 10.2 CDKN2A ERBB2
6 vulva adenocarcinoma 10.2 CDKN2A ERBB2
7 breast benign neoplasm 10.2 ERBB2 MME
8 thoracic benign neoplasm 10.2 ERBB2 MME
9 cervix endometriosis 10.2 CALB2 MME
10 malignant leydig cell tumor 10.2 CALB2 MME
11 adenofibroma 10.2 CALB2 MME
12 rete testis adenocarcinoma 10.2 CALB2 MME
13 wolffian tumor 10.2
14 mixed cell type cancer 10.2 ERBB2 MME
15 lymphohistiocytoid mesothelioma 10.2 CALB2 CDKN2A
16 ewing's family of tumors 10.2 CDKN2A ERBB2
17 spermatocele 10.2 CALB2 MME
18 acute lymphoblastic leukemia, childhood 10.2 CDKN2A MME
19 rete testis neoplasm 10.2 CALB2 MME
20 cystadenofibroma 10.2 CALB2 MME
21 tonsil cancer 10.1 CDKN2A ERBB2
22 liposarcoma 10.1 CALB2 CDKN2A
23 breast fibroadenoma 10.1 ERBB2 MME
24 mucinous bronchioloalveolar adenocarcinoma 10.1 CALB2 CDKN2A
25 barrett's adenocarcinoma 10.1 CDKN2A ERBB2
26 pancreatic mucinous cystadenoma 10.1 CALB2 MME
27 lung combined type small cell carcinoma 10.1 MME MYOG
28 in situ carcinoma 10.1 CDKN2A ERBB2
29 pleural cancer 10.1 CALB2 CDKN2A
30 esophageal disease 10.1 CDKN2A ERBB2
31 ovarian brenner tumor 10.1 CALB2 MME
32 leukemia, acute lymphoblastic 3 10.1 CDKN2A MME
33 carcinosarcoma 10.1 ERBB2 MME
34 conventional leiomyosarcoma 10.1 CDKN2A MYOG
35 bladder disease 10.1 CDKN2A ERBB2
36 nephrogenic adenofibroma 10.1 MME MYOG
37 respiratory system cancer 10.1 CDKN2A ERBB2
38 malignant pleural mesothelioma 10.0 CALB2 CDKN2A
39 acute lymphocytic leukemia 10.0 CDKN2A MME
40 endometrial adenocarcinoma 10.0 CDKN2A ERBB2
41 uterine carcinosarcoma 10.0 ERBB2 MME
42 spindle cell liposarcoma 10.0 CALB2 MYOG
43 early invasive cervical adenocarcinoma 10.0 CDKN2A INSM1
44 cervix uteri carcinoma in situ 10.0 CDKN2A INSM1
45 uterus carcinoma in situ 10.0 CDKN2A INSM1
46 cholangiocarcinoma 10.0 CDKN2A ERBB2 MME
47 renal cell carcinoma, papillary, 1 10.0 ERBB2 MME
48 microinvasive cervical squamous cell carcinoma 9.9 INSM1 PTPRN
49 reproductive system disease 9.9 CDKN2A ERBB2 PTPRN
50 lung cancer susceptibility 3 9.8 CALB2 CDKN2A ERBB2

Graphical network of the top 20 diseases related to Fallopian Tube Endometrioid Adenocarcinoma:



Diseases related to Fallopian Tube Endometrioid Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Endometrioid Adenocarcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 8.92 CALB2 CDKN2A ERBB2 MYOG

MGI Mouse Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 CDKN2A ERBB2 INSM1 MME MYOG PTPRN
2 respiratory system MP:0005388 8.92 CDKN2A ERBB2 INSM1 MYOG

Drugs & Therapeutics for Fallopian Tube Endometrioid Adenocarcinoma

Drugs for Fallopian Tube Endometrioid Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
4
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
5
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
6
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
7
Gemcitabine Approved Phase 2, Phase 3,Phase 3 95058-81-4 60750
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
12
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
13
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
14 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
15 Immunoglobulins Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 3,Phase 2,Phase 1
18 Immunoglobulin G Phase 3,Phase 2,Phase 1
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
20 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
21 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Immunologic Factors Phase 3,Phase 2,Phase 1
24 Antibodies Phase 3,Phase 2,Phase 1
25 Mitogens Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Micronutrients Phase 3
29 Carotenoids Phase 3
30 Trace Elements Phase 3
31 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
32 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
33 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
34 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
35 Protein Kinase Inhibitors Phase 2, Phase 3
36 topoisomerase I inhibitors Phase 2, Phase 3
37 taxane Phase 3
38 Antimetabolites Phase 3
39 Antimetabolites, Antineoplastic Phase 3
40 Immunosuppressive Agents Phase 3,Phase 2
41 Antiviral Agents Phase 3
42 Anti-Infective Agents Phase 3
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
46
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
47
Entinostat Investigational Phase 1, Phase 2 209783-80-2
48 Maytansine Phase 2
49 Immunoconjugates Phase 2
50 Antirheumatic Agents Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
4 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
5 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
8 Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03587311 Phase 2 Paclitaxel
9 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
10 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
11 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
12 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
13 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
14 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
15 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Not yet recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
16 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
17 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
18 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
19 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Fallopian Tube Endometrioid Adenocarcinoma

Genetic Tests for Fallopian Tube Endometrioid Adenocarcinoma

Anatomical Context for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Endometrioid Adenocarcinoma:

42
Breast, Cervix, Lung, Endothelial, Testis, Ovary, Uterus

Publications for Fallopian Tube Endometrioid Adenocarcinoma

Articles related to Fallopian Tube Endometrioid Adenocarcinoma:

# Title Authors Year
1
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a case of report and review of the literature. ( 19457622 )
2010
2
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review. ( 15991543 )
2005
3
Endometrioid carcinoma of the fallopian tube resembling a female adnexal tumor of probable wolffian origin. ( 15322493 )
2004
4
A case of endometrioid carcinoma of the fallopian tube mimicking an adnexal tumor of probable Wolffian origin. ( 10379682 )
1999
5
Primary endometrioid carcinoma of the fallopian tube. ( 8677782 )
1996
6
Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. ( 8946874 )
1996
7
Microcystic endometrioid carcinoma of the fallopian tube simulating an adnexal tumour of probable wolffian origin. ( 8314244 )
1993
8
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a report of six cases. ( 1582746 )
1992
9
Endometrioid carcinoma of the fallopian tube: pathology and clinical outcome. ( 1972104 )
1990
10
Endometrioid carcinoma of the fallopian tube. ( 683640 )
1978

Variations for Fallopian Tube Endometrioid Adenocarcinoma

Expression for Fallopian Tube Endometrioid Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Endometrioid Adenocarcinoma.

Pathways for Fallopian Tube Endometrioid Adenocarcinoma

Pathways related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.82 CDKN2A ERBB2
2 10.49 CDKN2A ERBB2

GO Terms for Fallopian Tube Endometrioid Adenocarcinoma

Biological processes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.5 CDKN2A INSM1 MYOG
2 cellular response to growth factor stimulus GO:0071363 9.26 ERBB2 MYOG
3 positive regulation of cell cycle arrest GO:0071158 9.16 INSM1 MYOG
4 replicative senescence GO:0090399 8.96 CDKN2A MME
5 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 CDKN2A ERBB2

Molecular functions related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin DNA binding GO:0031490 8.62 INSM1 MYOG

Sources for Fallopian Tube Endometrioid Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....